Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
MDxHealth (R): MDxHealth Signs Partnership with LifeLabs to Make SelectMDx available in Canada | ||||||
By: Nasdaq / GlobeNewswire - 14 Feb 2019 | Back to overview list |
|||||
NEWS RELEASE Under the terms of the partnership agreement, LifeLabs will serve as an exclusive distributor for SelectMDx in Canada. Liquid biopsy samples will be tested in MDxHealth's state-of-the-art clinical diagnostic laboratory in Irvine, California, and LifeLabs will reimburse MDxHealth for all testing services performed. SelectMDx, the only non-invasive liquid biopsy diagnostic test available to selectively identify patients at increased risk of aggressive prostate cancer on the basis of two RNA urine biomarkers, has been shown to have a significant impact on initial prostate biopsy decision-making. Today, the standard of care to identify patients with prostate cancer is based on invasive, and often painful, prostate biopsies. However, these procedures are often inaccurate and unnecessary, with 80% of men undergoing a biopsy having no cancer detected, of which about 25% are expected to harbor indolent cancer missed by the procedure. . In Canada, about 60,000 prostate biopsies are performed annually, resulting in about 24,000 newly diagnosed prostate cancer patients per year, while leaving about 1.4 million at-risk Canadian men living with increased prostate-specific-antigen (PSA) levels. The Canadian Cancer Society estimates that, by 2030, the number of patients diagnosed each year with prostate cancer will increase to 42,000 from 24,000 today, mainly driven by an ageing population and lifestyle. About SelectMDx® for Prostate Cancer About LifeLabs About MDxHealth® For more information:
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the Company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws. NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx, AssureMDx, PredictMDx and UrNCollect are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners. Attachment |
||||||
|
||||||
Copyright 2019 Nasdaq / GlobeNewswire | Back to overview list |